Selected article for: "influenza virus and novel virus"

Author: Jordan, Paul C; Stevens, Sarah K; Deval, Jerome
Title: Nucleosides for the treatment of respiratory RNA virus infections
  • Document date: 2018_3_21
  • ID: txaoz7oh_40
    Snippet: In this review, we summarized the exciting advances in discovery and development of novel nucleoside analogs as potential new treatments for respiratory RNA virus infections. The medical need is high because very few drugs have been approved for the treatment of respiratory viral infections despite worldwide health impacts attributed to them. The approved drugs include zanamivir, oseltamivir, peramivir, and favipiravir (Japan only) for influenza .....
    Document: In this review, we summarized the exciting advances in discovery and development of novel nucleoside analogs as potential new treatments for respiratory RNA virus infections. The medical need is high because very few drugs have been approved for the treatment of respiratory viral infections despite worldwide health impacts attributed to them. The approved drugs include zanamivir, oseltamivir, peramivir, and favipiravir (Japan only) for influenza virus and palivizumab for RSV, all of which have limitations that prevent their widespread use in a therapeutic setting. Drug candidates intended for use against rhinovirus infections, such as the capsid inhibitor pleconaril and the protease inhibitor rupintrivir, have been tested in the clinic without success.

    Search related documents:
    Co phrase search for related documents
    • clinic test and health impact: 1, 2
    • clinic test and influenza virus: 1
    • development discovery and drug candidate: 1, 2, 3, 4, 5, 6, 7, 8
    • development discovery and exciting advance: 1
    • development discovery and health impact: 1, 2, 3, 4, 5, 6
    • development discovery and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • development discovery and medical need: 1, 2, 3, 4, 5
    • development discovery and new treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • development discovery and respiratory viral infection: 1
    • drug candidate and health impact: 1
    • drug candidate and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • drug candidate and new treatment: 1, 2, 3, 4, 5, 6
    • drug candidate and nucleoside analog: 1, 2
    • health impact and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • health impact and medical need: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • health impact and new treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • health impact and nucleoside analog: 1, 2
    • health impact and respiratory viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • health impact and RNA virus infection: 1